145 related articles for article (PubMed ID: 37271979)
1. Effect of Cefoperazone/Sulbactam on Blood Coagulation Function in Infected Emergency Department Patients and the Necessity of Vitamin K1 (VK1) Preventive Intervention: A Single-Center, Retrospective Analysis.
Shao X; Ren Y; Xie N; Fan K; Sun H; Lu J; Wei J; Tian X
Med Sci Monit; 2023 Jun; 29():e939203. PubMed ID: 37271979
[TBL] [Abstract][Full Text] [Related]
2. A Comparison of Coagulation Function in Patients Receiving Aspirin and Cefoperazone-Sulbactam With and Without Vitamin K
Wu S; Wu G; Wu H
Clin Ther; 2021 Dec; 43(12):e335-e345. PubMed ID: 34819242
[TBL] [Abstract][Full Text] [Related]
3. Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study.
Wang W; Liu Y; Yu C; Tan J; Xiong W; Dong D; Li S; Zhang R; Li J; Wu Y; Zong Z; Su N; Zou K; Wu G; Sun X
Expert Opin Drug Saf; 2020 Mar; 19(3):339-347. PubMed ID: 31914329
[No Abstract] [Full Text] [Related]
4. Cefoperazone-sulbactam combination in the treatment of urinary tract infections: efficacy, safety, and effects on coagulation.
Greenberg RN; Reilly PM; Weinandt WJ; Bollinger M; Kennedy DJ
Clin Ther; 1987; 10(1):52-6. PubMed ID: 3329965
[TBL] [Abstract][Full Text] [Related]
5. Observation of clinical efficacy of the cefoperazone/sulbactam anti-infective regimen in the treatment of multidrug-resistant Acinetobacter baumannii lung infection.
Wang Q; Huang M; Zhou S
J Clin Pharm Ther; 2022 Jul; 47(7):1020-1027. PubMed ID: 35285526
[TBL] [Abstract][Full Text] [Related]
6. Comparison of antibiotic-associated diarrhea caused by cefoperazone/sulbactam or piperacillin/tazobactam in neurosurgery patients.
Chen Y; Xiang Q; Liu L
J Int Med Res; 2021 May; 49(5):3000605211019661. PubMed ID: 34057835
[TBL] [Abstract][Full Text] [Related]
7. Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia.
Liu JW; Chen YH; Lee WS; Lin JC; Huang CT; Lin HH; Liu YC; Chuang YC; Tang HJ; Chen YS; Ko WC; Lu MC; Wang FD
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138577
[TBL] [Abstract][Full Text] [Related]
8. Cefoperazone/sulbactam-induced hemolytic anemia.
Sun XM; Liu LH; Wu Q; Wang HG
J Postgrad Med; 2023; 69(1):46-49. PubMed ID: 34528516
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.
Hu J; Xiao YH; Zheng Y; Lai YX; Fang XL; Fang Q
Eur J Clin Pharmacol; 2020 Jul; 76(7):913-922. PubMed ID: 32355990
[TBL] [Abstract][Full Text] [Related]
10. [Clinical experience with the treatment of severe nosocomial infections by inhibitor-protected 3rd generation cephalosporin cefoperazone/sulbactam].
Beloborodova NV; Kuznetsova ST; Popov DA; Bachinskaia EN; Vostrikov TIu
Antibiot Khimioter; 2005; 50(4):33-40. PubMed ID: 16392338
[TBL] [Abstract][Full Text] [Related]
11. Cefoperazone-sulbactam for treatment of intra-abdominal infections: results from a randomized, parallel group study in India.
Chandra A; Dhar P; Dharap S; Goel A; Gupta R; Hardikar JV; Kapoor VK; Mathur AK; Modi P; Narwaria M; Ramesh MK; Ramesh H; Sastry RA; Shah S; Virk S; Sudheer OV; Sreevathsa MR; Varshney S; Kochhar P; Somasundaram S; Desai C; Schou M
Surg Infect (Larchmt); 2008 Jun; 9(3):367-76. PubMed ID: 18570578
[TBL] [Abstract][Full Text] [Related]
12. The effect of cefoperazone sulbactam and piperacillin tazobactam on mortality in Gram-negative nosocomial infections.
Guclu E; Kaya G; Ogutlu A; Karabay O
J Chemother; 2020 May; 32(3):118-123. PubMed ID: 32096456
[TBL] [Abstract][Full Text] [Related]
13. A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections.
Xin X; Jian L; Xia X; Jia B; Huang W; Li C; Wang C; Zhou L; Sun X; Tang X; Huang Y; Zhu Y; Zhang W
Ann Clin Microbiol Antimicrob; 2013 Dec; 12():38. PubMed ID: 24321187
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam.
Xia J; Zhang D; Xu Y; Gong M; Zhou Y; Fang X
Int J Infect Dis; 2014 Jun; 23():90-3. PubMed ID: 24726664
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant
Niu T; Luo Q; Li Y; Zhou Y; Yu W; Xiao Y
Antimicrob Resist Infect Control; 2019; 8():52. PubMed ID: 30886705
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and Influencing Factors of Coagulation Dysfunction Caused by Cefoperazone/Sulbactam.
Zeng J; Zou M; Min M; Xu M
Altern Ther Health Med; 2024 Jan; ():. PubMed ID: 38290444
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder.
Miao W; Guo J; Cheng H; Zhao Q
Infect Drug Resist; 2023; 16():6277-6284. PubMed ID: 37766881
[TBL] [Abstract][Full Text] [Related]
18. A fatal case of suspected anaphylaxis with cefoperazone and sulbactam: LC-MS analysis.
Tsujikawa K; Kuwayama K; Miyaguchi H; Kanamori T; Iwata Y; Inoue H; Kishi T
J Forensic Sci; 2008 Jan; 53(1):226-31. PubMed ID: 18279263
[TBL] [Abstract][Full Text] [Related]
19. Cefoperazone / sulbactam induced hyponatremia.
Mitra S; Basu S
Indian J Med Sci; 2006 Apr; 60(4):158-9. PubMed ID: 16679632
[No Abstract] [Full Text] [Related]
20. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.
Su J; Guo Q; Li Y; Wu S; Hu F; Xu S; Wang M
J Antimicrob Chemother; 2018 Nov; 73(11):3176-3180. PubMed ID: 30099554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
